The role of drugs in the induction and/or exacerbation of psoriasis
- PMID: 21091671
- DOI: 10.1111/j.1365-4632.2010.04570.x
The role of drugs in the induction and/or exacerbation of psoriasis
Abstract
Psoriasis is a common skin disorder; knowledge of the factors that may induce, trigger, or exacerbate the disease is of primary importance in clinical practice. Drug intake is a major concern in this respect, as new drugs are constantly being added to the list of factors that may influence the course of this disease. Drug ingestion may result in exacerbation of pre-existing psoriasis, in induction of psoriatic lesions on clinically uninvolved skin in patients with psoriasis, or in precipitation of the disease in persons without family history of psoriasis or in predisposed individuals. In view of their relationship to drug-provoked psoriasis, therapeutic agents may be classified as drugs with strong evidence for a causal relationship to psoriasis, drugs about which there are considerable but insufficient data to support the induction or aggravation of the disease, and drugs that are occasionally reported to be associated with aggravation or induction. This review focuses on the most common causative agents for drug-induced, drug-triggered, or drug-aggravated psoriasis, such as β-blockers, lithium, synthetic antimalarial drugs, nonsteroidal anti-inflammatory agents, and tetracyclines, and the mechanisms of action of these drugs in the pathogenesis of psoriasis.
© 2010 The International Society of Dermatology.
Comment in
-
The role of terbinafine in induction and/or exacerbation of psoriasis.Int J Dermatol. 2013 Sep;52(9):1155-6. doi: 10.1111/j.1365-4632.2011.05117.x. Epub 2012 Sep 24. Int J Dermatol. 2013. PMID: 22998455 No abstract available.
Similar articles
-
Psoriasis induced or aggravated by drugs.J Rheumatol Suppl. 2009 Aug;83:59-61. doi: 10.3899/jrheum.090227. J Rheumatol Suppl. 2009. PMID: 19661544
-
Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score.Cutan Ocul Toxicol. 2006;25(1):1-11. doi: 10.1080/15569520500536568. Cutan Ocul Toxicol. 2006. PMID: 16702050 Review.
-
Drug-induced psoriasis. Recognition and management.Am J Clin Dermatol. 2000 May-Jun;1(3):159-65. doi: 10.2165/00128071-200001030-00003. Am J Clin Dermatol. 2000. PMID: 11702297 Review.
-
The role of terbinafine in induction and/or exacerbation of psoriasis.Int J Dermatol. 2013 Sep;52(9):1155-6. doi: 10.1111/j.1365-4632.2011.05117.x. Epub 2012 Sep 24. Int J Dermatol. 2013. PMID: 22998455 No abstract available.
-
Diagnosis of drug-induced psoriasis.Semin Dermatol. 1992 Dec;11(4):269-74. Semin Dermatol. 1992. PMID: 1362889 Review.
Cited by
-
Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level.Cureus. 2020 Jul 2;12(7):e8964. doi: 10.7759/cureus.8964. Cureus. 2020. PMID: 32766006 Free PMC article. Review.
-
Apoptotic or Antiproliferative Activity of Natural Products against Keratinocytes for the Treatment of Psoriasis.Int J Mol Sci. 2019 May 24;20(10):2558. doi: 10.3390/ijms20102558. Int J Mol Sci. 2019. PMID: 31137673 Free PMC article. Review.
-
The role of xenobiotics in triggering psoriasis.Arch Toxicol. 2020 Dec;94(12):3959-3982. doi: 10.1007/s00204-020-02870-8. Epub 2020 Aug 24. Arch Toxicol. 2020. PMID: 32833044 Review.
-
A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis.Dermatoendocrinol. 2013 Jan 1;5(1):222-34. doi: 10.4161/derm.24808. Dermatoendocrinol. 2013. PMID: 24494059 Free PMC article.
-
Norepinephrine and adenosine-5'-triphosphate synergize in inducing IL-6 production by human dermal microvascular endothelial cells.Cytokine. 2013 Nov;64(2):605-12. doi: 10.1016/j.cyto.2013.08.005. Epub 2013 Sep 8. Cytokine. 2013. PMID: 24026137 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical